Abstract
Type 2 diabetes mellitus (T2DM) is a highly prevalent and progressive metabolic disease associated with significant morbidity and mortality. While glycemic control remains the cornerstone of disease treatment, successful T2DM management requires consideration of several comorbid risk factors including overweight/obesity, dyslipidemia, and hypertension. Early and aggressive treatment of patients with T2DM should be implemented to slow disease progression and prevent long-term complications. This necessitates the selection of antidiabetes agents that effectively lower hyperglycemia and target the other fundamental defects of T2DM. Treatment regimens should be individualized according to patient profiles and risk factors. This is especially germane for overweight/obese patients with T2DM, who have an even higher risk for complications. Several newer antidiabetes agents, in particular, incretin-based therapies, target the underlying defects of T2DM, provide glycemic control with beneficial effects on cardiovascular risk factors including lipids and blood pressure while avoiding weight gain. These represent important therapeutic options for the management of patients with T2DM.
Keywords: Drug therapy, exenatide, GLP-1 receptor agonists, glycemic control, incretins, obesity, type 2 diabetes mellitus
Current Drug Therapy
Title: Incretin-Based Therapies in Patients with Type 2 Diabetes
Volume: 5 Issue: 2
Author(s): Jeffrey S. Freeman, DO
Affiliation:
Keywords: Drug therapy, exenatide, GLP-1 receptor agonists, glycemic control, incretins, obesity, type 2 diabetes mellitus
Abstract: Type 2 diabetes mellitus (T2DM) is a highly prevalent and progressive metabolic disease associated with significant morbidity and mortality. While glycemic control remains the cornerstone of disease treatment, successful T2DM management requires consideration of several comorbid risk factors including overweight/obesity, dyslipidemia, and hypertension. Early and aggressive treatment of patients with T2DM should be implemented to slow disease progression and prevent long-term complications. This necessitates the selection of antidiabetes agents that effectively lower hyperglycemia and target the other fundamental defects of T2DM. Treatment regimens should be individualized according to patient profiles and risk factors. This is especially germane for overweight/obese patients with T2DM, who have an even higher risk for complications. Several newer antidiabetes agents, in particular, incretin-based therapies, target the underlying defects of T2DM, provide glycemic control with beneficial effects on cardiovascular risk factors including lipids and blood pressure while avoiding weight gain. These represent important therapeutic options for the management of patients with T2DM.
Export Options
About this article
Cite this article as:
S. Freeman, DO Jeffrey, Incretin-Based Therapies in Patients with Type 2 Diabetes, Current Drug Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157488510791065094
DOI https://dx.doi.org/10.2174/157488510791065094 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
SNP Technologies for Drug Discovery: A Current Review
Current Drug Discovery Technologies Medicinal Agents in the Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Recent Advance in Isoform-Specific Regulation of Adenylyl Cyclase
Current Enzyme Inhibition Manoglanistara - Emotional Wellness Phases Prediction of Adolescent Female Students by using Brain Waves
Current Signal Transduction Therapy Nanomedicine for Intranasal Delivery to Improve Brain Uptake
Current Drug Delivery Alcohol Consumption, Dementia and Cognitive Decline: An Overview of Systematic Reviews
Current Clinical Pharmacology Epidemiological Aspects of Stroke in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets Intra-Renal Hemodynamic Changes After Habitual Physical Activity in Patients with Chronic Kidney Disease
Current Pharmaceutical Design Novel Biomarkers Assessing Renal Function in Heart Failure: Relation to Inflammatory Status and Cardiac Remodelling
Current Medicinal Chemistry Tissue Distribution and Pharmacodynamics: A Complicated Relationship
Current Drug Metabolism A Systematic Review of Overweight, Obesity, and Type 2 Diabetes Among Asian American Subgroups
Current Diabetes Reviews Clinical Science of Calcium Channel Blocker to Inhibit Hypertensive Vascular Injury
Current Hypertension Reviews Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design Author Index To Volume 2
Current Hypertension Reviews In Silico Validation for the Modulatory Effect of Tea Catechins on Erythrocyte Na<sup>+</sup>/K<sup>+</sup>-ATPase
The Natural Products Journal Cellular and Biochemical Alterations Caused by Artificial Depletion of Glutathione
Current Enzyme Inhibition The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Is Beta-Blocker Treatment Associated with a Decrease in the Risk of Cancer
Letters in Drug Design & Discovery Kv1.5-Kvβ Interactions: Molecular Determinants and Pharmacological Consequences
Mini-Reviews in Medicinal Chemistry